Search

everythinglearnresearchcommunity

for

Search:↓

Dupilumab helped a woman with severe hair loss regrow her hair quickly and maintain it for six months after stopping treatment.

People with alopecia areata have much lower Vitamin-D levels than healthy individuals.

Alopecia areata involves immune system imbalances that may lead to depression and anxiety.

Higher miR-34a levels and the A variant of the MIR-34A gene are linked to increased risk and severity of alopecia areata.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.

Alopecia areata is a chronic condition causing hair loss, with new treatments targeting the immune system showing promise.

There are two main types of alopecia areata with different severity, and diagnosis is made through clinical examination and trichoscopy, influencing treatment choices.

Both Th1 and Th2 immune responses are increased in alopecia areata, with Th2 response more strongly linked to how severe the disease is.

Latanoprost 0.005% solution safely increases hair density and regrowth in scalp alopecia areata.

There are significant gaps and inconsistencies in diagnosing and treating alopecia areata in Greece and Italy.

Alopecia areata significantly lowers quality of life, especially in personal and social areas, and more so if the patient is also depressed.

Experts agreed on guidelines to improve research on Frontal Fibrosing Alopecia.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

TGPC plus CGT is effective and safe for treating severe alopecia areata in children.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

Combining TRA and latanoprost is most effective for treating localized alopecia areata.

Alopecia areata severely impacts quality of life, causing anxiety, depression, and work impairment.

Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.

No link between scalp patterns and alopecia severity in children, but more severe cases often had nail abnormalities.

The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.

The Brigham Eyebrow Tool for Alopecia is a simple and reliable way to measure eyebrow hair loss.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Combining calcipotriol and PRP is most effective for treating Alopecia Areata.

Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.

Higher MIF levels in alopecia areata patients suggest it could be a treatment target and disease predictor.

Higher levels of CCL7 are linked to more severe hair loss in alopecia areata patients.

Alopecia Areata greatly affects the quality of life and mental health of Canadian patients and their caregivers.

Alopecia areata significantly lowers the quality of life, especially in emotional and mental health aspects.

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.